Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337878 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05337878 is a Phase 1 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT05337878, a Phase 1 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of Pelacarsen (ISIS 681257) in healthy Japanese participants.
Interventions
- DRUG Placebo
- DRUG Pelacarsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05337878
The ClinicalTrials.gov registry entry for NCT05337878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05337878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05337878 about?
NCT05337878 is a clinical study titled "A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants". The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of Pelacarsen (ISIS 681257) in healthy Japanese participants.
What is the current status of trial NCT05337878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-10-15. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT05337878?
The interventions under investigation include: Placebo (DRUG), Pelacarsen (DRUG).
Who is sponsoring clinical trial NCT05337878?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.